SHINE Medical Technologies is a pharmaceutical company which is building a facility to produce radioactive isotopes for medical applications.
SHINE is dedicated to being the world leader in the safe, clean, affordable production of medical tracers and cancer treatment elements.
SHINE was founded in 2010 by Greg Piefer and is a development-stage company working toward becoming the world-leading medical isotope producer. The company has its headquarter based in Janesville, Wisconsin.
The SHINE technology offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the existing global supply chain for molybdenum-99.
SHINE’s advanced accelerator technology enables a high-yield molybdenum-99 (moly‑99 or Mo-99) production process that is safer, cleaner, more affordable and fits seamlessly into the existing moly-99 supply chain.
SHINE already has long-term supply contracts with two of the three North American Mo-99 distributors, GE Healthcare (GE) and Lantheus Medical Imaging, as well as HTA, the largest Chinese producer, and distributor of radiopharmaceuticals.
SHINE is backed by Koch Disruptive Technologies (KDT), Baillie Gifford, Fidelity Management and Research Company, Oaktree Capital Management, Deerfield Management Company, and others. The company raised $150M in Series C-5 round on Jun 28, 2021. This brings SHINE's total funding to $490M to date.